Cargando…

Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia

BACKGROUND: About 20–30% of patients with schizophrenia develop tardive dyskinesia (TD). Oxidative stress is one potential causes of TD. CYP2E1 is considered as an oxidative stress-related gene, however, no study has been reported on the DNA methylation levels of the CYP2E1 in schizophrenia or TD. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ping, Li, Yanli, Wang, Kesheng, Huang, Junchao, Su, Brenda Bin, Xu, Chun, Wang, Zhiren, Tan, Shuping, Yang, Fude, Tan, Yunlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733323/
https://www.ncbi.nlm.nih.gov/pubmed/36494682
http://dx.doi.org/10.1186/s12920-022-01404-8
_version_ 1784846347093934080
author Zhang, Ping
Li, Yanli
Wang, Kesheng
Huang, Junchao
Su, Brenda Bin
Xu, Chun
Wang, Zhiren
Tan, Shuping
Yang, Fude
Tan, Yunlong
author_facet Zhang, Ping
Li, Yanli
Wang, Kesheng
Huang, Junchao
Su, Brenda Bin
Xu, Chun
Wang, Zhiren
Tan, Shuping
Yang, Fude
Tan, Yunlong
author_sort Zhang, Ping
collection PubMed
description BACKGROUND: About 20–30% of patients with schizophrenia develop tardive dyskinesia (TD). Oxidative stress is one potential causes of TD. CYP2E1 is considered as an oxidative stress-related gene, however, no study has been reported on the DNA methylation levels of the CYP2E1 in schizophrenia or TD. METHODS: A total of 35 schizophrenia patients with TD, 35 schizophrenia patients without TD (NTD), and 35 health controls (HCs) were collected in Beijing, China. DNA was extracted from peripheral blood samples. The promoter methylation levels of CYP2E1 were detected using pyrosequencing. The generalized linear model (GLM) was used to examine the methylation levels of three CpG sites among three diagnostic groups (TD vs. NTD vs. HC). RESULTS: The average methylation levels were 8.8 ± 10.0, 14.5 ± 11.9 and 15.1 ± 11.3 in TD, NTD and HC groups, respectively. The F-test in GLM revealed overall differences in the average of methylation levels of three CpG sites among three diagnostic groups (p = 0.0227) and in the third CpG site (p = 0.0026). Furthermore, the TD group had lower average methylation levels than HC and NTD groups (p = 0.0115 and 0.0268, respectively). Specifically, TD group showed lower methylation levels in the third CpG site than HC and NTD groups (p = 0.0012 and 0.0072, respectively). Additionally, associations of the methylation levels with clinical features in the TD group were observed using Spearman correlation analysis. CONCLUSION: This study provides the first evidence of DNA methylation levels in the promoter of CYP2E1 gene associated with schizophrenia and TD. The abnormal DNA methylation might serve as a potential mechanism for TD.
format Online
Article
Text
id pubmed-9733323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97333232022-12-10 Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia Zhang, Ping Li, Yanli Wang, Kesheng Huang, Junchao Su, Brenda Bin Xu, Chun Wang, Zhiren Tan, Shuping Yang, Fude Tan, Yunlong BMC Med Genomics Research Article BACKGROUND: About 20–30% of patients with schizophrenia develop tardive dyskinesia (TD). Oxidative stress is one potential causes of TD. CYP2E1 is considered as an oxidative stress-related gene, however, no study has been reported on the DNA methylation levels of the CYP2E1 in schizophrenia or TD. METHODS: A total of 35 schizophrenia patients with TD, 35 schizophrenia patients without TD (NTD), and 35 health controls (HCs) were collected in Beijing, China. DNA was extracted from peripheral blood samples. The promoter methylation levels of CYP2E1 were detected using pyrosequencing. The generalized linear model (GLM) was used to examine the methylation levels of three CpG sites among three diagnostic groups (TD vs. NTD vs. HC). RESULTS: The average methylation levels were 8.8 ± 10.0, 14.5 ± 11.9 and 15.1 ± 11.3 in TD, NTD and HC groups, respectively. The F-test in GLM revealed overall differences in the average of methylation levels of three CpG sites among three diagnostic groups (p = 0.0227) and in the third CpG site (p = 0.0026). Furthermore, the TD group had lower average methylation levels than HC and NTD groups (p = 0.0115 and 0.0268, respectively). Specifically, TD group showed lower methylation levels in the third CpG site than HC and NTD groups (p = 0.0012 and 0.0072, respectively). Additionally, associations of the methylation levels with clinical features in the TD group were observed using Spearman correlation analysis. CONCLUSION: This study provides the first evidence of DNA methylation levels in the promoter of CYP2E1 gene associated with schizophrenia and TD. The abnormal DNA methylation might serve as a potential mechanism for TD. BioMed Central 2022-12-09 /pmc/articles/PMC9733323/ /pubmed/36494682 http://dx.doi.org/10.1186/s12920-022-01404-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhang, Ping
Li, Yanli
Wang, Kesheng
Huang, Junchao
Su, Brenda Bin
Xu, Chun
Wang, Zhiren
Tan, Shuping
Yang, Fude
Tan, Yunlong
Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
title Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
title_full Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
title_fullStr Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
title_full_unstemmed Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
title_short Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
title_sort altered dna methylation of cyp2e1 gene in schizophrenia patients with tardive dyskinesia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733323/
https://www.ncbi.nlm.nih.gov/pubmed/36494682
http://dx.doi.org/10.1186/s12920-022-01404-8
work_keys_str_mv AT zhangping altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT liyanli altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT wangkesheng altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT huangjunchao altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT subrendabin altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT xuchun altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT wangzhiren altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT tanshuping altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT yangfude altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia
AT tanyunlong altereddnamethylationofcyp2e1geneinschizophreniapatientswithtardivedyskinesia